Why Tango Therapeutics (TNGX) Is Down 12.4% After Gilead Exit, Wider Loss And Board Changes - And What's Next
Tango Therapeutics (TNGX) saw its stock drop 12.4% after reporting a wider Q1 2026 net loss of US$45.51 million and the end of its collaboration revenue with Gilead. The company also announced board resignations but highlighted US$379.80 million in cash, expected to fund operations into 2028, and ongoing progress in its precision oncology pipeline. The investment narrative focuses on the reliance on unproven trials to justify spending without near-term profitability, especially following the loss of the Gilead partnership.
Assessing Tango Therapeutics (TNGX) Valuation After Trial Progress And Leadership Changes
Tango Therapeutics (TNGX) recently reported a net loss of US$45.51m for the first quarter, alongside clinical progress updates and executive changes. Despite recent share price declines, the company still shows strong year-to-date and one-year returns. The article questions whether Tango Therapeutics is undervalued, noting its high Price-to-Book ratio of 7.6x compared to industry averages, driven by investor premium despite the company operating at a loss.
Piper Sandler downgrades Tango Therapeutics stock rating on strategy shift By Investing.com
Piper Sandler downgraded Tango Therapeutics (NASDAQ:TNGX) to Neutral from Overweight due to a potential shift in the company's development strategy for vopimetostat, prioritizing a RAS combination approach over monotherapy. Despite raising the price target to $24.00, concerns were raised about the lack of clarity on monotherapy data and the stock's significant surge over the past year while remaining unprofitable. The firm also noted potential future catalysts focusing on competitor drug candidates, influencing the downgrade given Tango's high valuation and market capitalization.
Vanguard Group Inc. Has $59.81 Million Holdings in Tango Therapeutics, Inc. $TNGX
Vanguard Group Inc. significantly increased its stake in Tango Therapeutics, Inc. by 33.6% in the fourth quarter, bringing its total holdings to nearly $60 million. Institutional ownership of Tango Therapeutics remains high at 78.99%, despite some insider selling. Analysts generally rate the stock as a "Moderate Buy" with a consensus price target of $31.36, even after the company reported a quarterly loss consistent with expectations.
[SCHEDULE 13G/A] Tango Therapeutics, Inc. Amended Passive Investment Disclosure
TCG Crossover II entities and Chen Yu have filed an amended Schedule 13G/A for Tango Therapeutics, Inc. (TNGX), disclosing beneficial ownership of 11,597,737 shares of common stock, which represents 8.1% of the class. This figure includes 1,066,666 shares underlying pre-funded warrants exercisable within 60 days, with a beneficial ownership limitation capping exercises at 9.99%. The filing clarifies that TCG Crossover GP II, with Chen Yu as its managing member, shares voting and dispositive power over these securities.
Nextech Crossover reports 7.27M-share stake in Tango Therapeutics (TNGX)
Nextech Crossover I SCSp and related entities disclosed a beneficial ownership of 7,266,081 shares, or 5.1%, of Tango Therapeutics (TNGX) common stock as of March 31, 2026. This information was reported in an amended passive investment disclosure (Schedule 13G/A). The filing clarifies the ownership and control structure, noting Nextech Crossover I GP S.a. r.l. as the general partner, with Ian Charoub, Costas Constantinides, and Rocco Sgobbo having power to direct voting and disposition, while explicitly disclaiming status as a "group."
Piper Sandler downgrades Tango Therapeutics stock rating on strategy shift
Piper Sandler downgraded Tango Therapeutics (NASDAQ:TNGX) to Neutral from Overweight, citing a potential shift in the company's development strategy for vopimetostat in pancreatic cancer and concerns about current valuation. Despite the downgrade, Piper Sandler increased its price target to $24.00. The company's stock has surged over 1,500% in the past year, trading near its 52-week high, even as it remains unprofitable.
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $30.1, Implies 18% Upside
Tango Therapeutics, Inc. (TNGX) has seen its average 12-month price target raised from $23.9 to $30.1 by 10 analysts, with a range of $16 to $55 per share. This updated target implies an 18% potential upside from its May 13 closing price. The consensus rating for the stock remains "Buy" from 12 covering analysts.
Tango Therapeutics price target raised to $33 from $19 at Wedbush
Wedbush has increased its price target for Tango Therapeutics (TNGX) to $33 from $19, maintaining an Outperform rating. This adjustment reflects recent financing activities and the progression of vopimetostat development. The firm anticipates further updates on PRMT5i assets and data later this year.
Tango Therapeutics Is Maintained at Outperform by Wedbush
Wedbush has maintained its Outperform rating on Tango Therapeutics. The article likely discusses the reasons behind this rating, but the content shared is incomplete.
Tango Therapeutics Reshapes Board Amid Late-Stage Progress
Tango Therapeutics announced significant board changes, including two resignations and the appointment of Sung Lee as Lead Independent Director, as it progresses towards late-stage clinical development. The company reported a Q1 2026 net loss of $45.5 million but maintains a strong cash position of $379.8 million, projected to fund operations into 2028. Tango is advancing its oncology programs, with a focus on vopimetostat for pancreatic cancer, and its stock currently holds a "Buy" rating from analysts with a $40.00 price target.
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics reported its financial results for the first quarter ended March 31, 2026, with a cash position of $380 million providing runway into 2028. The company is advancing vopimetostat towards pivotal development in pancreatic cancer, with initial clinical data from combination trials expected in 2026. Tango also announced key leadership appointments and provided updates on its broader pipeline, including upcoming milestones for vopimetostat in lung cancer and TNG456 in glioblastoma.
Earnings Flash (TNGX) Tango Therapeutics, Inc. Reports Q1 Revenue $0
Tango Therapeutics, Inc. (TNGX) reported Q1 revenue of $0. The article also provides recent news about the company, including insider share sales, CFO appointments, and updated analyst price targets. Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets for cancer treatment.
Tango Therapeutics (NASDAQ: TNGX) widens Q1 loss but holds $380M cash runway
Tango Therapeutics reported a widened net loss of $45.5 million in Q1 2026, or $0.32 per share, compared to $39.9 million a year prior. Despite the increased loss due to zero collaboration revenue after the Gilead partnership ended and higher general and administrative expenses, the company maintains a strong cash position of $379.8 million. This cash runway is expected to fund operations into 2028, supporting its oncology pipeline advancement, including key clinical milestones for vopimetostat and TNG456.
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics announced its first-quarter 2026 financial results and provided business updates. The company reported a cash position of $380 million as of March 31, 2026, with a runway into 2028, and anticipates presenting first clinical data from its PRMT5/RAS(ON) combination trial later in 2026. Tango is focusing on advancing vopimetostat towards pivotal development in pancreatic cancer and strengthening its leadership team to support late-stage clinical programs.
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics announced its first quarter 2026 financial results, highlighted by a cash position of $380 million, providing runway into 2028. The company is advancing vopimetostat towards pivotal development in pancreatic cancer, with initial clinical data from its combination trial with RAS(ON) inhibitors expected in 2026. Key leadership appointments were also made to support the late-stage development of vopimetostat and the broader pipeline.
Investors brace for Tango Therapeutics earnings amid combo hopes By Investing.com
Tango Therapeutics is set to report its first-quarter earnings, with analysts anticipating a loss of 31 cents per share on significantly reduced revenue. Despite the lack of profitability, the clinical-stage biotech has seen its stock perform well in 2026, driven by optimism around its cancer drug combination strategy, particularly involving its PRMT5 inhibitor vopimetostat and RAS inhibitors. Investors are closely watching for updates on clinical trials and the company's cash runway as it moves towards pivotal trials and expects first-in-human combination data in 2026.
Farallon (TNGX) reports 9.10M shares and 2.16M warrants in amendment
Farallon Capital has filed an amendment (SCHEDULE 13G/A) disclosing its beneficial ownership in Tango Therapeutics, Inc. The filing indicates that various Farallon Funds collectively hold 9,097,411 shares and 2,159,792 pre-funded common stock purchase warrants, with these warrants considered exercisable within 60 days for reporting purposes. The Warrants are subject to a 9.99% Beneficial Ownership Limitation.
Stifel Remains Bullish on Tango Therapeutics (TNGX)
Stifel maintained a Buy rating and increased its price target for Tango Therapeutics (TNGX) to $40, citing high conviction in the synergy of its PRMT5 inhibitor + RAS(ON) inhibitor in pancreatic cancer. Tango Therapeutics, a clinical-stage biotechnology company, reported $343.1 million in cash and equivalents, expected to fund operations into 2028. The article also touches on AI investment opportunities, suggesting some AI stocks may offer higher and quicker returns than TNGX.
Daniella Beckman exits Tango Therapeutics as CFO; separation agreement details
Daniella Beckman is no longer serving as the Chief Financial Officer, principal accounting officer, and principal financial officer for Tango Therapeutics, effective April 15, 2026. A separation agreement was entered into on May 7, 2026, which includes 12 months of severance pay, COBRA reimbursement, accelerated vesting for some awards, and extended post-termination option exercise. The reason for her departure and her replacement information were not disclosed.
Tango Therapeutics Finalizes Separation Agreement with Former CFO
Tango Therapeutics announced that it has finalized a separation agreement with its former CFO, Daniella Beckman, who departed on May 1, 2026. The agreement includes 12 months of severance pay, COBRA reimbursement, and accelerated vesting of stock options and restricted stock units. Despite weak financial performance, TipRanks’ AI Analyst, Spark, rates TNGX as Neutral, noting strong technical momentum.
Tango Therapeutics finalizes separation agreement with former CFO Daniella Beckman
Tango Therapeutics announced it has finalized a separation agreement with former CFO Daniella Beckman, whose employment ended on April 15, 2026. Under the terms, Beckman will receive 12 months of her base salary as severance and COBRA reimbursements, and her outstanding stock options and RSUs will have accelerated vesting for an additional 24 months, with an extended exercise period. This agreement follows her previously disclosed departure and comes as Tango Therapeutics has experienced a significant stock surge, although InvestingPro suggests it is overvalued despite a strong balance sheet.
CFO Daniella Beckman exit terms at Tango Therapeutics (NASDAQ: TNGX)
Tango Therapeutics (NASDAQ: TNGX) has detailed the separation terms for its former Chief Financial Officer, Daniella Beckman, following her departure effective April 15, 2026. Under the separation agreement, Ms. Beckman will receive 12 months of severance pay, COBRA premium reimbursements for 12 months, and accelerated vesting of stock options and restricted stock units equivalent to an additional 24 months of service. Her post-termination stock option exercise period is also extended through August 31, 2026, contingent on her signing a general release in favor of the company.
5 Best Performing Healthcare Stocks So Far in 2026
Tango Therapeutics, Inc. (NASDAQ:TNGX) is highlighted as one of the best-performing healthcare stocks in 2026 with a year-to-date share price gain of 171.01%. Stifel maintained a Buy rating and increased its price target to $40, citing elevated conviction for the company's PRMT5 inhibitor + RAS(ON) inhibitor synergy. Tango Therapeutics, a clinical-stage biotechnology company, reported $343.1 million in cash and equivalents, expected to fund operations into 2028, despite a decrease in collaboration revenue for Q4 2025.
How Leadership Shuffle, Pivotal Trial Plans And Pan-RAS Deal At Tango Therapeutics (TNGX) Has Changed Its Investment Story
Tango Therapeutics is undergoing significant changes, including a leadership shuffle with Malte Peters appointed CEO and Barbara Weber moving to Executive Chair. The company has also outlined plans for pivotal trials and secured a pan-RAS supply agreement, alongside granting equity awards to its new CFO and another employee. These developments signify Tango's strategic alignment towards critical clinical milestones and enhanced partnership execution, though investors should remain cautious about future financing and potential dilution.
How Leadership Shuffle, Pivotal Trial Plans And Pan-RAS Deal At Tango Therapeutics (TNGX) Has Changed Its Investment Story
Tango Therapeutics recently announced leadership changes, including the appointment of Malte Peters as CEO, along with plans for pivotal trials and a pan-RAS supply agreement. These developments, coupled with new equity awards for key personnel, aim to align the company's evolving structure with upcoming clinical milestones and partnership execution. While the core investment thesis remains centered on its precision oncology pipeline, investors are urged to consider potential risks related to future financing and dilution, as the company prepares for more complex trials.
[SCHEDULE 13G] Tango Therapeutics, Inc. Passive Investment Disclosure (>5%)
FMR LLC and Abigail P. Johnson have filed a Schedule 13G for Tango Therapeutics, Inc. (TNGX), disclosing beneficial ownership of 9,905,919 shares, which represents 6.9% of the company's common stock. This is a passive investment disclosure, indicating that the shares were acquired in the ordinary course of business and not for the purpose of influencing company control. The filing details voting and dispositive power for FMR LLC and Ms. Johnson, and includes the CUSIP number and issuer address.
Tango Therapeutics Insider Sold Shares Worth $573,097, According to a Recent SEC Filing
An insider at Tango Therapeutics (TNGX) recently sold shares valued at $573,097, as disclosed in a Securities and Exchange Commission (SEC) filing. Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicine for cancer treatment by identifying novel drug targets. The company's pipeline includes programs like TNG908, TNG260, TNG348, and TNG462, all aimed at various cancer-related targets.
Tango Therapeutics president, R&D Adam Crystal sells $573k in shares
Adam Crystal, President of Research & Development at Tango Therapeutics (NASDAQ:TNGX), sold 27,000 shares for $573,097 after exercising options. These transactions were executed under a Rule 10b5-1 trading plan established in October 2025. Following the sales, Crystal directly holds 115,743 shares and 368,040 derivative shares, amid positive analyst updates and a new CFO appointment for Tango Therapeutics.
Tango Therapeutics (TNGX) R&D president exercises 27K options, sells 27K shares
Crystal Adam, President of R&D at Tango Therapeutics (TNGX), executed an exercise-and-sell transaction on May 1, 2026. She exercised 27,000 stock options at $5.20 per share and subsequently sold all 27,000 common shares in two open-market transactions at weighted average prices of $21.9964 and $21.1931 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan established on October 27, 2025.
Tango Therapeutics (TNGX) CFO receives 40,000 RSUs and 240,000 options
Matthew Gall, CFO of Tango Therapeutics (TNGX), was granted 40,000 Restricted Stock Units (RSUs) and options for 240,000 shares of common stock. The RSUs will vest over three years, specifically on May 10, 2027, May 10, 2028, and May 9, 2029, contingent on his continuous service. The stock options, with an exercise price of $20.98, will vest 25% on April 15, 2027, with the remainder vesting in 36 equal monthly installments, also subject to his continued employment.
Assessing Tango Therapeutics (TNGX) Valuation After Leadership Changes And New Pan RAS Supply Agreement
Tango Therapeutics (TNGX) has experienced significant stock volatility following leadership changes, a new supply agreement for pan RAS, and pipeline updates. The company is currently trading at a Price-to-Book (P/B) ratio of 9.5x, notably higher than the industry average, which suggests it may be overvalued. Investors are advised to consider key risks and potential future performance of trials before making investment decisions.
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics announced inducement grants of non-qualified stock options and restricted stock units (RSUs) to its Chief Financial Officer, Matthew Gall, and a new employee. These grants, made under the 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), incentivize their employment with the company. The options and RSUs have specific vesting schedules tied to continued employment, with the option exercise price set at the closing price of Tango Therapeutics' common stock on May 1, 2026.
Invus and Avicenna disclose passive stakes in Tango Therapeutics (NASDAQ: TNGX)
An amended Schedule 13G/A filing reveals that Invus Public Equities holds approximately 3.5% of Tango Therapeutics (NASDAQ: TNGX), while Avicenna Life Sci Master Fund holds about 0.5%. Raymond Debbane is deemed a beneficial owner of around 4.0% through related entities. These stakes are reported as passive, indicating no intent to control or influence the company.
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics announced that its Compensation Committee granted inducement equity awards to its Chief Financial Officer, Matthew Gall, and a new employee. These grants, including non-qualified stock options and restricted stock units (RSUs), were made under the company's 2023 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The awards vest over several years, contingent on continued employment.
Stifel reiterates Tango Therapeutics stock Buy rating at $15
Stifel has reiterated its Buy rating and $15 price target for Tango Therapeutics (NASDAQ:TNGX) following the company's Q4 2025 financial results. Despite a net loss, the stock has seen a significant surge over the past year, and the company maintains a strong cash position providing a runway into 2028. Recent developments include a new Chief Regulatory Officer, an Outperform rating from Mizuho, and leadership changes.
Jefferies raises Tango Therapeutics stock price target on RAS deal
Jefferies has increased its price target for Tango Therapeutics (NASDAQ:TNGX) shares to $18 from $14, maintaining a Buy rating. This adjustment follows a supply agreement with ERAS for pan-RAS and anticipated positive data from Revolution Medicines, which could lead to Tango Therapeutics' combination therapy enhancing treatment efficacy. The company also reported a net loss for Q4 2025 and full-year 2025, and announced a new CEO and board member.
TNGX Technical Analysis | Trend, Signals & Chart Patterns | TANGO THERAPEUTICS INC (NASDAQ:TNGX)
This article provides a detailed technical analysis of TANGO THERAPEUTICS INC (TNGX), assigning it a strong technical rating of 9 out of 10. It highlights TNGX as a steady performer in the Biotechnology industry with a positive long-term trend, though it currently trades neutrally in the short term. The analysis also covers its performance metrics, trend indicators, and support/resistance levels, advising a wait for consolidation due to recent price volatility.
Tango Therapeutics (TNGX) director receives RSU and option grants as board compensation
Tango Therapeutics director Lee Sung received 12,300 restricted stock units (RSUs) and an option for 5,200 shares as part of his board compensation. The RSUs will vest in three equal annual installments starting January 2, 2027, and the stock option, with an exercise price of $22.06, will vest monthly over three years beginning January 2, 2026, both contingent on his continued service. This transaction is classified as routine non-employee director compensation rather than open-market trading.
TNGX (NASDAQ: TNGX) affiliate files to sell 65,460 shares after option exercise
An affiliate of Tango Therapeutics (TNGX) has filed a Form 144 to sell 65,460 common shares on May 1, 2026, stemming from the exercise of stock options for cash. The filing also details several prior 10b5-1 sales by Adam Crystal earlier in 2026, including their respective share counts and proceeds. This Form 144 submission provides transparency regarding the upcoming stock sale and past insider transactions.
Tango Therapeutics (NASDAQ:TNGX) Trading Down 9.7% - Here's What Happened
Tango Therapeutics (NASDAQ:TNGX) experienced a 9.7% midday stock price drop to $22.71 on Wednesday, with trading volume significantly below its daily average. Despite the decline, analysts maintain a "Moderate Buy" rating with an average target price of $22.44. The clinical-stage biotech company, which has a market cap of $3.18 billion and negative earnings, has also seen notable insider selling recently.
The Nasdaq Biotechnology Index closed down more than 1.2%. Among its constituent stocks, Tango Therapeutics fell by 12.25%, Personalis dropped 8.36%, PTC Therapeutics decreased by 8.13%, Foghorn slid 8.12%, and Erasca declined 7.98%.
The Nasdaq Biotechnology Index experienced a decline of over 1.2%. Several constituent stocks saw significant drops, including Tango Therapeutics, Personalis, PTC Therapeutics, Foghorn, and Erasca. Conversely, some stocks like Biogen, Agios Pharmaceuticals, First Tracks Biotherapeutics, Design Therapeutics, and KalVista Pharmaceuticals recorded substantial gains.
Tango Therapeutics (TNGX) price target increased by 11.68% to 24.38
This article reports a significant increase in Tango Therapeutics' (TNGX) price target. The new target is set at $24.38, representing an 11.68% increase. This adjustment reflects updated analyst expectations for the company.
Tango Therapeutics (TNGX) price target increased by 11.68% to 24.38
This article reports that Tango Therapeutics (TNGX) has seen its price target increased by 11.68%. The new price target for TNGX is set at $24.38.
How New C-Suite Hires At Tango Therapeutics (TNGX) Have Changed Its Investment Story
Tango Therapeutics recently announced new C-suite hires, including a CFO and development leaders, bringing extensive experience to the company. While the core investment narrative still revolves around its precision oncology pipeline and clinical data, these appointments could positively influence spending, trial execution, and capital planning. Investors will be watching to see if these management changes translate into tangible improvements in funding risk and execution credibility, especially given concerns about potential overvaluation and recent dilution.
Stifel raises Tango Therapeutics stock price target on drug combo potential
Stifel raised its price target for Tango Therapeutics Inc. (NASDAQ:TNGX) to $40 from $24, maintaining a Buy rating, due to increased conviction in the synergy of its PRMT5 inhibitor and RAS(ON) inhibitor combination for pancreatic cancer. The firm anticipates improved objective response rates and duration of response with the drug combination, potentially leading to FDA Breakthrough Designation. Tango Therapeutics is expected to present first-in-human data for the combination in 2026 and provide guidance on a Phase 3 monotherapy study.
Tango Therapeutics (TNGX) price target increased by 32.09% to 20.06
Tango Therapeutics (TNGX) has seen its price target increased by 32.09% to $20.06. This adjustment reflects a significant uplift in the potential valuation of the company's stock.
Stifel raises Tango Therapeutics stock price target on drug combo potential
Stifel has increased its price target for Tango Therapeutics Inc. (NASDAQ:TNGX) to $40 from $24, maintaining a Buy rating due to strong conviction in the potential of the company's PRMT5 inhibitor and RAS(ON) inhibitor combination for pancreatic cancer. The firm anticipates the combination will significantly improve objective response rates and duration of response compared to monotherapy. Tango Therapeutics plans to present initial human data for this combination in 2026, with successful outcomes potentially leading to a timing advantage for a Phase 3 study and possible FDA Breakthrough Designation.
Tango Therapeutics (TNGX) price target increased by 32.09% to 20.06
This article reports a significant increase in Tango Therapeutics (TNGX) price target, which has risen by 32.09% to $20.06. This adjustment suggests a more optimistic outlook on the company's future stock performance.
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by Brokerages
Tango Therapeutics (NASDAQ:TNGX) has received a "Moderate Buy" consensus rating from twelve research firms, with an average one-year price target of $20.67. The company's stock shows strong market performance, opening at $25.75 and trading above its moving averages, despite remaining unprofitable with an anticipated -$1.34 EPS for the current fiscal year. Insider selling occurred last quarter, but institutional investors have significantly increased their positions, owning 78.99% of the company.
